Kyle Diamantas leads trader consensus as acting FDA commissioner since Marty Makary's May 2026 resignation, yet reports indicate he is not seeking the permanent role, leaving the White House actively reviewing other candidates amid ongoing policy priorities on food safety and regulatory reform. The sizable share for no announcement by year-end reflects the deliberate pace of Trump administration nominations requiring Senate confirmation, with limited public signals on finalists in recent weeks. Lower-priced names such as Brett Giroir, Stephen Hahn, Sara Brenner, and Grace Graham remain in play as potential contenders, but none have emerged with clear momentum. Upcoming developments including any formal nomination or White House statements could quickly shift positioning in this closely contested market.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedBrett Giroir 8.8%
Stephen Hahn 6.0%
Sara Brenner 5.8%
Grace Graham 3.8%
$18,745 Vol.
$18,745 Vol.
Dec 31, 2026
Kyle Diamantas
38%
Stephen Hahn
6%
Brett Giroir
9%
Grace Graham
4%
Sara Brenner
6%
No announcement by December 31
32%
Brett Giroir 8.8%
Stephen Hahn 6.0%
Sara Brenner 5.8%
Grace Graham 3.8%
$18,745 Vol.
$18,745 Vol.
Dec 31, 2026
Kyle Diamantas
$6,046 Vol.
38%
Stephen Hahn
$1,751 Vol.
6%
Brett Giroir
$2,967 Vol.
9%
Grace Graham
$4,151 Vol.
4%
Sara Brenner
$2,798 Vol.
6%
No announcement by December 31
$1,032 Vol.
32%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas leads trader consensus as acting FDA commissioner since Marty Makary's May 2026 resignation, yet reports indicate he is not seeking the permanent role, leaving the White House actively reviewing other candidates amid ongoing policy priorities on food safety and regulatory reform. The sizable share for no announcement by year-end reflects the deliberate pace of Trump administration nominations requiring Senate confirmation, with limited public signals on finalists in recent weeks. Lower-priced names such as Brett Giroir, Stephen Hahn, Sara Brenner, and Grace Graham remain in play as potential contenders, but none have emerged with clear momentum. Upcoming developments including any formal nomination or White House statements could quickly shift positioning in this closely contested market.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Market Opened: May 12, 2026, 7:59 PM ET
Volume
$18,745End Date
Dec 31, 2026Market Opened
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas leads trader consensus as acting FDA commissioner since Marty Makary's May 2026 resignation, yet reports indicate he is not seeking the permanent role, leaving the White House actively reviewing other candidates amid ongoing policy priorities on food safety and regulatory reform. The sizable share for no announcement by year-end reflects the deliberate pace of Trump administration nominations requiring Senate confirmation, with limited public signals on finalists in recent weeks. Lower-priced names such as Brett Giroir, Stephen Hahn, Sara Brenner, and Grace Graham remain in play as potential contenders, but none have emerged with clear momentum. Upcoming developments including any formal nomination or White House statements could quickly shift positioning in this closely contested market.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$18,745End Date
Dec 31, 2026Market Opened
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Kyle Diamantas leads trader consensus as acting FDA commissioner since Marty Makary's May 2026 resignation, yet reports indicate he is not seeking the permanent role, leaving the White House actively reviewing other candidates amid ongoing policy priorities on food safety and regulatory reform. The sizable share for no announcement by year-end reflects the deliberate pace of Trump administration nominations requiring Senate confirmation, with limited public signals on finalists in recent weeks. Lower-priced names such as Brett Giroir, Stephen Hahn, Sara Brenner, and Grace Graham remain in play as potential contenders, but none have emerged with clear momentum. Upcoming developments including any formal nomination or White House statements could quickly shift positioning in this closely contested market.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions